A naukri.com initiative
Bioengineer
2w
177
Image Credit: Bioengineer
High-Dose EGFR-TKIs Plus Pemetrexed Combat NSCLC
- A recent study has shown promising results with the combined use of high-dose third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) and intrathecal pemetrexed in treating leptomeningeal metastases in advanced non-small-cell lung cancer (NSCLC) patients with EGFR mutations.
- Leptomeningeal metastases are highly challenging, occurring when cancer cells spread to the membranes surrounding the brain and spinal cord, leading to severe neurological symptoms.
- The study involved treating 23 patients with EGFR-mutant NSCLC and leptomeningeal metastases using elevated doses of EGFR-TKIs alongside intrathecal pemetrexed to enhance intracranial tumor suppression.
- Results showed over 90% of patients experiencing intracranial symptom relief and an intracranial disease control rate of almost 87%, with a median intracranial progression-free survival of ten months and overall survival of twelve months.
- The combination therapy demonstrated manageable adverse events, predominantly mild to moderate myelosuppression, with rare severe incidents reported.
- Favorable prognostic factors included good performance status and concurrent administration of bevacizumab, showing potential synergistic effects on survival outcomes.
- The study highlights the importance of innovative treatment strategies in managing leptomeningeal metastases and improving patient outcomes by addressing systemic and intracranial disease simultaneously.
- Optimizing dosage and scheduling of therapies, along with exploring combination with other systemic agents like immunotherapies, may further enhance treatment efficacy.
- While the study was retrospective and had a limited patient cohort, its findings lay the groundwork for future prospective clinical trials to validate and refine treatment standards.
- The integrated approach of using high-dose EGFR-TKIs and intrathecal pemetrexed signifies a significant advancement in precision oncology for treating leptomeningeal metastases in EGFR-mutant NSCLC, offering hope for improved patient outcomes.
Read Full Article
10 Likes
For uninterrupted reading, download the app